the PENPACT-1 (PENTA 9/PACTG 390) Study Team Abstract Background-The PENPACT-1 trial compared virologic thresholds to determine when to switch to second-line antiretroviral therapy (ART). Using PENPACT-1 data, we aimed to describe HIV-1 drug resistance accumulation on first-line ART by virologic threshold.
Introduction
Pediatric guidelines [1-3] recommend HIV-1 infected children initiate antiretroviral therapy (ART) early in life. Since ART dramatically reduces mortality, duration of this treatment is likely to be long; potentially for many decades. Historically, children have tended to be maintained on failing therapies longer than adults, due to challenges with adherence and limited treatment options. This is particularly true in resource-limited settings where HIV-1 RNA monitoring is generally not available. HIV-1 drug resistance is known to increase with continuation of the same ART regimen in the presence of detectable viremia. Therefore, long-term treatment success requires effective first-line therapies, minimization of resistant virus on these therapies, and preservation of second line options. Careful consideration is required when sequencing ART regimens, taking into account first-line ART exposure, acquisition of resistance mutations on first-line, and exposure to ART as part of programs to reduce mother to child transmission (MTCT).
The PENPACT-1 trial [4] is the only long-term strategy trial in children or adults to assess effectiveness of first-line ART regimens as well as randomized RNA thresholds (1000 or 30000c/ml) to determine when to switch to second-line. Over time, a 1000c/ml threshold has been adopted to define virologic failure, followed by prompt switch to second-line in adults, but direct evidence for this threshold remains weak. When PENPACT-1 was designed in the early 2000s, drug choice for children was limited, and switch to second-line could be delayed due to concerns that drug options would be quickly exhausted, therefore a threshold ~1.5log 10 c/ml higher than 1000c/ml, above assay variation, was chosen to reflect practice at the time. In children, current recommendations for when to switch still vary, with the consolidated WHO guidelines [1] recommending a switch time consistent with adults and the US and European guidelines [2, 3] instead recommending assessment of reasons for virologic failure and consideration of drug availability, resistance profiles, adherence issues and readiness of the family/child to switch.
Using data on all children from PENPACT-1, we explored resistance profiles after first-line ART by randomized switch-criteria based on RNA threshold, as well as second-line treatment response and drug options in children. The hypothesis was that more resistance mutations would accumulate on first-line ART in children randomized to the higher threshold, and this would influence second-line response as well as available second-line drug options.
Methods
PENPACT-1 was a multicenter phase 2/3, randomized, open-label, 2 by 2 factorial trial enrolling HIV-1 infected children from clinical centers in Europe and North and South America, with a minimum follow-up of 4 years [4] . Children were naïve to ART, although infants who had received <56 days of ART to reduce MTCT were eligible. Children were simultaneously randomized to start ART with two NRTIs plus either a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI) and to switch from firstline to second-line ART at an RNA threshold of 1000c/ml (low-threshold) or 30000c/ml (higher-threshold). First-line ART was defined as the initial regimen, allowing drug substitutions (ideally within the same class) for non-virologic reasons (e.g. toxicity). The initial regimen was chosen by the treating clinician according to the randomized group. Children were switched to second-line if the RNA threshold (<1000c/ml or <30000c/ml) was not achieved by week 24, or if after an initial decline in RNA by week 24 there was a confirmed RNA rebound at/above the randomized threshold. Switch to second-line was also required if the child experienced a new CDC stage C event at/after week 24. For analysis purposes, children were defined in both arms as reaching the '1000 criteria' and '30000 criteria' using the above definition. Children who received first-line containing a PI were strongly encouraged to switch to a second-line containing an NNRTI, and vice-versa. Children had RNA measured at enrollment, weeks 8, 16, 24, and then 12 weekly until the last enrolled child reached 4 years.
Baseline resistance tests were performed on samples collected within 84 days before randomization. During follow-up, the overall aim was to evaluate new HIV-1 drug resistance mutations accumulated on first-line. As children were randomized to early (lowthreshold) versus later (higher-threshold) switch-points, requirements for resistance testing aimed to identify additional mutations accumulated if a policy to switch at the '30000 criteria' compared to the '1000 criteria' was applied. To capture this, resistance tests were required in both RNA threshold arms, while children were on ART, at 1) the last sample with RNA ≥1000c/ml before switch, 2) the last sample after confirmed RNA ≥1000c/ml (e.g. if not switched because '30000 criteria' not met and RNA re-suppressed to <1000c/ml), and 3) samples with RNA ≥1000c/ml at 4 years or trial end. To further visualize the requirements for switch and resistance testing, we have provided a Supplemental Figure displaying a set of example RNA profiles. It can be seen that children in the higherthreshold arm would be tested later when we hypothesize more resistance mutations will have accumulated. It can also be noted, that some RNA profiles required multiple tests per child. Major resistance mutations were defined according to International AIDS Society-USA (IAS) guidelines [5] . New mutations on first-line were accumulated over post-baseline tests [6] . Susceptibility to specific ART drugs was defined as fully susceptible, potential low-level, low-level, intermediate and high-level resistance by the genotypic resistance interpretation algorithm available on the Stanford University HIV drug resistance database webpage [7] . Genotypic sensitivity from this algorithm was formulated for current WHO recommended second-lines.
In this analysis, unlike the primary publication [4] , 4 children who started a drug class (PI or NNRTI) different to their randomization were grouped based on the drug class actually started, rather than the strict intent-to-treat definition based on randomized class. Proportions of children reaching criteria were tested using chi-squared tests, time to reach switch-criteria and to actual switch used Kaplan-Meier methods and log-rank tests, and comparison of time to resistance tests and RNA levels used Wilcoxon rank-sum tests. Poisson regression, without a time offset, tested differences in number of mutations by group. The model assumed children not requiring resistance tests did not develop mutations and excluded those with missing test results. For second-line efficacy, a child was considered successful if they achieved <400c/ml 24 weeks after switch. Proportions of children <400c/ml were calculated from Kaplan-Meier curves and comparisons used Cox regression. Analysis used Stata statistical software. Table 1 shows baseline age, HIV-1 RNA, resistance, HIV-1 subtype, prior ART use for reduction of MTCT and first-line ART for the 263 children enrolled in PENPACT-1 initiating therapy and included in this analysis. Other baseline characteristics have previously been published [4] . Median (range) age at start of ART was 6.5 (0.1-17.8) years. Thirty-nine children (15%) received ART for reduction of MTCT; most zidovudine prophylaxis alone and only 5 (2%) received single-dose nevirapine. Four percent (10/239) of baseline samples tested retrospectively had ≥1 major mutation. Of children starting PI based ART, 65 (50%) started lopinavir/ritonavir and 64 (49%) nelfinavir, whereas for children starting NNRTIs, 82 (62%) started efavirenz and 50 (38%) nevirapine. For NRTIs, 166 (63%) initiated lamivudine+zidovudine or stavudine, 62 (24%) abacavir+lamivudine and 35 (13%) other NRTI combinations (mainly lamivudine+didanosine).
Results

Baseline Characteristics and First-line ART
Children Reaching the 1000c/ml and 30000c/ml switching criteria
By trial end, at a median follow-up of 5.0 years (IQR 4.2-6.0), 94 children (36%) had reached the '1000 criteria' (51 low-threshold, 43 higher-threshold, chi-squared P=0.42). These 94 children were evenly distributed by drug class; 51 (54%) started PIs and 43 (46%) NNRTIs (chi-squared P=0.42). Median RNA when the '1000 criteria' were met was 13505c/ml for those on PIs and 9800c/ml for NNRTIs (Wilcoxon rank-sum P=0.49). As expected, most children in the low-threshold arm switched soon after reaching the '1000 criteria' (median time to switch after reaching '1000 criteria': 12 weeks). This time was similar in children starting PIs (12 weeks) and NNRTIs (8 weeks, log-rank P=0.60) [ Figure  1 , solid-line]. Of 43 children in the higher-threshold arm who reached the '1000 criteria', 3 (7%) switched before subsequently reaching the '30000 criteria', 22 (55%) reached the '30000 criteria' before trial end (18 switched), and the remaining 18 (42%) neither reached the '30000 criteria' nor switched. The median time from reaching the '1000 criteria' to the '30000 criteria' was 80 weeks [ Figure 1 , dotted-dashed-line]. This observed time was longer for those starting NNRTIs (median 80 weeks) compared to PIs (median 58 weeks), although not significantly different (log-rank P=0.81). However, there was an observed shorter time from reaching the '1000 criteria' to switch for those on NNRTIs (25 th percentile: 17 weeks) compared to PIs (25 th percentile: 63 weeks, log-rank P=0.16) [ Figure 1 , solid-dashed-line]. The median RNA when the '30000 criteria' were met was 54991c/ml (NNRTIs 44550c/ml versus PIs 69649c/ml, Wilcoxon rank-sum P=0.09).
Resistance Tests Required and Performed
In total, 107 children required resistance tests ( Table 2 ). This included 90/94 children reaching the '1000 criteria' and 17 additional children. The 4 children reaching the '1000 criteria' not requiring tests were due to 1 child switching at a CDC stage C event with suppressed RNA and 3 being off ART for all RNAs ≥1000c/ml. The 17 additional tests were due to single RNA ≥1000c/ml at 4 years, trial end or before switch. These 107 children required 127 tests on first-line; 90 (84%) required one test, 14 (13%) two tests and 3 (3%) three tests. The reasons for requiring resistance tests were 1) last sample with RNA ≥1000c/ml before switch (n=58), 2) last sample after confirmed RNA ≥1000c/ml (e.g. if not switched because '30000 criteria' not met and RNA re-suppressed to <1000c/ml) (n=24), and 3) samples with RNA ≥1000c/ml at 4 years or trial end (n=45) (See the Supplemental Figure for example RNA profiles and resistance testing requirements). Overall, 101/127 (80%) tests were available for 87/107 (81%) children. The 20 children with missing test results were similarly distributed across first-line regimen and randomized switch-thresholds (chi-squared on 3 degrees of freedom P=0.76). For 87 children with available resistance tests on first-line, median time from randomization to last resistance test was 72 weeks in the low-threshold and 124 weeks in the higher-threshold arm (Wilcoxon rank-sum P=0.009). For PIs this was 50 versus 121 weeks (P=0.01) and for NNRTIs 95 versus 148 weeks (P=0.35). Table 2 displays new major IAS resistance mutations accumulated on first-line. More NRTI mutations accumulated in NNRTI-higher than the other 3 groups, with more children selecting ≥3 mutations in NNRTI-higher driving this difference (Poisson P<0.001). Overall, more NNRTI than PI mutations accumulated (Poisson P<0.001). It appeared that NNRTI mutations had already been selected before switching at the '1000 criteria' as NNRTI-low had a similar number of mutations to NNRTI-higher. PI mutations were developed by 16% in PI-low and 7% in PI-higher; note more nelfinavir was administered in PI-low. For nonrandomized NRTIs, 5 (9%) on abacavir+lamivudine, 39 (25%) on lamivudine+zidovudine or stavudine, and 6 (21%) on other NRTI combinations developed mutations (Poisson P<0.01). Figure 2 provides a detailed description of first-line ART administered and mutations accumulated. It reveals, in PI-low and PI-higher, very few PI mutations were selected by children on lopinavir/ritonavir and relatively more on nelfinavir. On lopinavir/ritonavir the main NRTI mutation selected was M184V, but on nelfinavir additional NRTI mutations were accumulated. All 5 children who developed NRTI mutations on abacavir+lamivudine were on NNRTIs, whereas 22/39 (56%) children on lamivudine+zidovudine or stavudine with mutations were on NNRTIs and 17/39 (44%) on PIs. Figure 3 displays susceptibility to potential second-line regimens. All children on first-line abacavir+lamivudine with lopinavir/ritonavir were fully susceptible to WHO recommended second-line lamivudine+zidovudine with efavirenz in PI-low and PI-higher. Eleven (73%) in PI-low and 20 (87%) in PI-higher were fully susceptible to WHO recommended second-line after first-line lamivudine+zidovudine or stavudine with lopinavir/ritonavir. After first-line abacavir+lamivudine with an NNRTI, 14 (82%) in NNRTI-low and 12 (80%) in NNRTIhigher were fully susceptible to second-line lamivudine+zidovudine with lopinavir/ritonavir. After first-line lamivudine+zidovudine or stavudine with an NNRTI, 32 (80%) in NNRTIlow and 26 (65%) in NNRTI-higher were fully susceptible to second-line lamivudine +abacavir or tenofovir with lopinavir/ritonavir. This likely reflects accumulation of thymidine analogue mutations (TAMs) on zidovudine or stavudine.
HIV-1 Resistance Mutations Accumulated on First-line ART
Susceptibility to Potential Second-line ART
Second-line Response
Sixty children switched to second-line during PENPACT-1 (20 PI-low, 8 PI-higher, 17 NNRTI-low, 15 NNRTI-higher). Five switched before reaching the '1000 criteria' (3 lowthreshold, 2 higher-threshold) and 55 (34 low-threshold, 21 higher-threshold) after they were met; 18 of the 21 in the higher-threshold arm waited until the '30000 criteria' were met, but 3 did not. The proportion <400c/ml by 24 weeks on second-line was 79% in PI-low, 63% PI-higher, 64% NNRTI-low and 100% NNRTI-higher (Cox regression P=0.10). Of 46/60 children with resistance data on first-line, 18 (39%) had no NRTI mutations, 22 (48%) 1-2 NRTI mutations and 6 (13%) ≥3 NRTI mutations (all 6 were in NNRTI-higher). Of those without NRTI resistance, 93% suppressed to <400c/ml by 24 weeks on second-line, whereas for those with 1-2 NRTI mutations, 65% suppressed, and those with ≥3 NRTI mutations, 100% suppressed (Cox regression P=0.64). The Supplemental list provides a detailed description of these children.
Discussion
Throughout the world children continue to initiate both NNRTI and PI-based first-line regimens in national treatment programs. Our long-term trial including a wide age range of children starting first-line PIs and NNRTIs provided a unique opportunity to study development of HIV-1 drug resistance and gain insight into resistance consequences of different ART switching strategies. Overall and as predicted, we found that children starting NNRTIs accumulated more HIV-1 drug resistance than those starting PIs. In particular, children switching later on NNRTIs accumulated more NRTI mutations, whereas on PIs, NRTI mutations did not accumulate over the time taken to reach a 30000c/ml threshold. Children taking the currently recommended lopinavir/ritonavir selected even fewer mutations than those on the un-boosted PI, nelfinavir, which is no longer recommended. Furthermore, in this study, before tenofovir was available in children (now approved by the FDA for children >2 years), there was a resistance benefit for children prescribed first-line abacavir+lamivudine compared to lamivudine+zidovudine or stavudine, but randomized evidence to verify this finding is required.
Over approximately 5 years on ART, suppression on first-line regimens was good with only around one third of children ever reaching the '1000 criteria' for switch. Of those, the observed time from 1000 to 30000 criteria was slightly longer for NNRTIs compared to PIs, but time from '1000 criteria' to switch was longer for PIs than NNRTIs. This suggests children failing on NNRTIs spent a slightly longer time with RNA between 1000 and 30000c/ml with prompt switch once the '30000 criteria' were met. In contrast, children on PIs spent a slightly shorter time with RNA between 1000 and 30000c/ml but the treating clinician had a tendency to wait to switch after the '30000 criteria' were met; possibly due to assessment of adequate adherence before switching to an NNRTI-based second-line. Despite this tendency to wait to switch on PIs, which hypothetically would result in more resistance mutations, we still saw less resistance accumulate in PI-higher compared to NNRTI-higher. These data are consistent with clinical trials and observational studies in adults, reporting fewer NRTI mutations on PIs than NNRTIs [8, 9] , as well as additional reports on accumulation of NRTI resistance on NNRTIs [10] [11] [12] .
As well as the overall protective effect of PIs, we saw fewer NRTI and PI resistance mutations for children on the boosted PI lopinavir/ritonavir compared to other PIs (mainly un-boosted nelfinavir). This is consistent with a systematic review of drug resistance after first-line failure in children [13] , which observed that the type of PI affected development of resistance. In particular, on nelfinavir, where adequate plasma concentrations are seldom reached in children [14] , D30N and N88S, specific nelfinavir mutations, were frequently reported. The review did not describe NRTI mutations by PI exposure, but our data suggest PI choice is likely to be important as lopinavir/ritonavir appeared particularly protective against accumulation of NRTI mutations. This is supported by CHER trial data [15] where only 11/331 (3%) children initiating lopinavir/ritonavir based first-line developed NRTI mutations, 10 of which developed M184V alone and no TAMs were seen.
To our knowledge, PENPACT-1 is the only trial of randomized criteria for switching from first to second-line ART based on RNA thresholds. There has been one small short-term trial where highly ART experienced adults were randomized to immediate or deferred switch [16] , and two trials comparing monitoring strategies with resistance data by arm [17, 18] . In the small ART experienced trial [18] , median time to meeting criteria was >60 weeks suggesting a similar delayed switch time to our study. A trend towards more new mutations in the deferred-switch compared to the immediate-switch arm was observed, with most new mutations to NRTIs, particularly TAMs. However, particular drugs or drug classes could not be assessed. The first monitoring trial [17] compared CD4 to RNA monitoring and revealed no difference in a future drug options score between arms. However more patients in the CD4 arm, which had a longer duration >400 c/ml, had ≥3 NRTI mutations. The only two patients who developed TAMs were in the CD4 arm. These data are consistent with our study, showing a low barrier to development of lamivudine and NNRTI resistance, which is similar in the two arms, but documentation of TAM accumulation in the arm with longer duration of virologic failure. The other monitoring trial [18] , compared laboratory and clinical monitoring to clinical monitoring alone, and showed a similar number of patients with major mutations in the clinical monitoring alone versus the laboratory and clinical monitoring arm. The authors noted that switching occurred late after first detectable RNA in the laboratory and clinical monitoring arm, which may account for the fact no differences were seen.
Since the advent of triple therapy two randomized trials [19, 20] on NRTI backbones in children suggest abacavir+lamivudine has similar or better efficacy compared to other NRTI combinations. Our data add to the current weight of evidence that prescribing an NRTI backbone of abacavir+lamivudine first-line followed by zidovudine in second-line has some resistance advantages, as previously described in the PENTA-5 trial [21] . For children prescribed abacavir+lamivudine in combination with lopinavir/ritonavir, we did not detect any resistance, and in combination with NNRTIs we only saw 5 children with NRTI resistance. The abacavir specific mutations do not affect susceptibility to second-line zidovudine and there is evidence that K65R induces hyper-susceptibility to zidovudine [22] . Conversely, using zidovudine (or stavudine) first-line results in accumulation of TAMs such that the efficacy of abacavir second-line is reduced. Overall accumulation of NRTI resistance on lamivudine+zidovudine or stavudine was greater than on abacavir+lamivudine with TAMs occurring in 10 children (including 1 on lopinavir/ritonavir), suggesting abacavir+lamivudine has beneficial resistance properties when prescribed first-line with lopinavir/ritonavir or NNRTIs. More than 2 TAMs accumulated for 4 children on lamivudine+zidovudine or stavudine and 5 children developed mutations from the TAM type 1 pathway which is known to have a negative impact on response to abacavir [22] . Additionally, the M184V mutation, present in nearly all children developing resistance on first-line, increases susceptibility to thymidine analogues (zidovudine and stavudine) but causes low-level resistance to abacavir [22] . Therefore, these data support a resistance benefit of prescribing abacavir+lamivudine first-line in settings where children may spend longer with high RNAs due to limited laboratory monitoring or unavailable second-line regimens.
Our data on efficacy of second-line are limited by the small number of children switching by trial end. However, the data suggests a similar (or maybe better) suppression rate after failing in the NNRTI-higher arm. The effect of NRTI resistance prior to switch on secondline efficacy revealed a consistent pattern, suggesting children who had developed 1-2 NRTI mutations on first-line did worst and those with ≥3 mutations best. In our data there was no evidence that clinicians selected more potent second-line regimens for children known to be failing with extensive resistance, so one could hypothesize that a boosted PI with partially effective NRTIs is sufficiently potent to suppress virus at least until week 24 of second-line. Alternatively, it may be that adherence more than drug resistance influences second-line success; two studies in adults [23, 24] with resistance tests prior to switch from an NNRTI to PI based ART found either no association of NRTI resistance with the success of secondline or paradoxically a higher suppression rate in those with resistance. The authors of the second study found evidence from pharmacokinetic drug levels that it was indeed adherence rather than drug resistance that influenced second-line success.
Conclusions
This study confirms the protective effect of a boosted PI against accumulation of HIV-1 drug resistance mutations, as reported in adult studies. Analysis of non-randomized NRTI backbones suggests abacavir+lamivudine results in fewer resistance mutations than lamivudine+zidovudine or stavudine, whether prescribed with an NNRTI or lopinavir/ ritonavir. Overall, these data support WHO 2013 pediatric guidelines [1] recommending abacavir+lamivudine as the first-line NRTI backbone with an NNRTI, and provide reassurance that despite the possibility of considerable time spent on first-line with detectable viremia (where HIV-1 RNA monitoring is not available), response to second-line with a boosted PI and zidovudine+lamivudine is expected to be good.
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Refer to Web version on PubMed Central for supplementary material. Major IAS resistance mutations accumulated on first-line antiretroviral therapy (ART). Children are displayed in 4 groups defined by the class of ART initiated as first-line (PIbased versus NNRTI-based) and their randomized switch threshold (low=1000c/ml versus higher=30000c/ml). Resistance tests were required on first-line in both randomized switch threshold arms, while children were on ART, at 1) the last sample with RNA ≥1000c/ml before switch, 2) the last sample after confirmed RNA ≥1000c/ml (e.g. if not switched because '30000 criteria' not met and RNA re-suppressed to <1000c/ml), and 3) samples with Second-line antiretroviral therapy (ART) options. Children are displayed in 4 groups defined by the class of ART initiated as first-line (PI-based versus NNRTI-based) and their randomized switch threshold (low=1000c/ml versus higher=30000c/ml). The clinician chosen initial first-line ART is displayed along with current WHO recommended secondline and the susceptibility to this potential second-line regimen by the Stanford algorithm. The proportion of children susceptible to the potential second-line options assumed that children not meeting requirements for resistance testing were susceptible and excludes children with unavailable resistance results. Second-line containing EFV is only recommended for children >3 years and has been noted on the figure. PI=protease inhibitor, NNRTI=non-nucleoside reverse transcriptase inhibitor, NRTI=nucleoside reverse transcriptase inhibitor, 3TC=lamivudine, FTC=emtricitabine, d4T=stavudine, Table 2 Major IAS Resistance Mutations Accumulated on first-line ART ** Resistance tests were required on first-line, while children were on ART, at 1) the last sample with RNA ≥1000c/ml before switch, 2) the last sample after confirmed RNA ≥1000c/ml (e.g. if not switched because '30000 criteria' not met and RNA re-suppressed to <1000c/ml), and 3) samples with RNA ≥1000c/ml at 4 years or trial end. IAS major resistance mutations were accumulated across multiple tests per child on first-line, where appropriate. The table displays number of children requiring tests and the number of children with test results, rather than the absolute number of tests performed. Children are displayed in 4 groups defined by the class of ART initiated as first-line (PI-based versus NNRTI-based) and their randomized switch threshold (low=1000c/ml, higher=30000c/ml). IAS = International AIDS Society-USA, ART = antiretroviral therapy, PI = protease inhibitor, NNRTI = non-nucleoside reverse transcriptase inhibitor, NRTI = nucleoside reverse transcriptase inhibitor, ABC = abacavir, 3TC = lamivudine, ZDV = zidovudine, d4T = stavudine, ddI = didanosine
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